(HealthDay News) – For adults at high cardiovascular risk with impaired glucose tolerance, baseline and change in objectively-assessed ambulatory activity are associated with reduced risk of cardiovascular events, according to a study published online Dec. 20 in The Lancet.
Thomas Yates, PhD, from the NIHR Leicester-Loughborough Diet, Lifestyle, and Physical Activity Biomedical Research Unit in the United Kingdom, and colleagues examined the correlation between baseline and change in ambulatory activity and the risk of cardiovascular events. The authors used data from 9,306 participants from the NAVIGATOR trial with impaired glucose tolerance and with existing cardiovascular disease or with at least one cardiovascular risk factor. Participants were followed for an average of six years for cardiovascular events (defined as cardiovascular mortality, non-fatal stroke, or myocardial infarction). Ambulatory activity was measured at baseline and 12 months by pedometer.
The researchers identified 531 cardiovascular events during 45,211 person-years of follow-up. Both baseline ambulatory activity and change in ambulatory activity correlated inversely with cardiovascular event risk (hazard ratios per 2,000 steps per day, 0.90 and 0.92, respectively). The association for change in ambulatory activity persisted after adjustment for changes in body mass index and other potentially confounding variables at 12 months.
“In individuals at high cardiovascular risk with impaired glucose tolerance, both baseline levels of daily ambulatory activity and change in ambulatory activity display a graded inverse association with the subsequent risk of a cardiovascular event,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which funded the study.